POSTSTROKE DEPRESSION


Cite item

Full Text

Abstract

Depression is one of the factors that can impair the functional outcome in patients after stroke. The article highlights the problems of diagnosis, clinical manifestation and approaches to the treatment of poststroke depression. Currently, selective serotonin reuptake inhibitors (SSRIs) are more widely used for the treatment of depression in patients with stroke. These include citalopram, escitalopram, fluoxetine, etc. Some authors consider prophylactic use of antidepressants from SSRI group for prevention of development of poststroke depression as reasonable method of treatment, particularly in patients with depressive disorders in anamnesis.

References

  1. Гехт А.Б., Боголепова А.Н., Сорокина И.Б. Депрессия после инсульта: опыт применения ципрамила // Журнал неврологии и психиатрии 2002. Т. 102. № 5. С. 36-40.
  2. Гехт А.Б., Сорокина И.Б., Боголепова А.Н. и соавт. Опыт применения иксела (милнаципрана гидрохлорида) в лечении постинсультной депрессии // Терапевтический архив 2003. Т. 75. № 10. С. 34-8.
  3. Гусев Е.И., Гехт А.Б. Реабилитация в неврологии. Учебное пособие. М., 2000.
  4. Гусев Е.И., Гехт А.Б., Боголепова А.Н., Сорокина И.Б. Особенности депрессивного синдрома у больных, перенесших ишемический инсульт // Журнал неврологии и психиатрии, приложение "Инсульт" 2001. №. 3. С. 28-31.
  5. Смулевич А. Б. Депрессии в общемедицинской практике. М., 2000.
  6. Сорокина И.Б. Депрессия у больных ишемическим инсультом. Дисс. канд. мед. наук. М., 2005.
  7. Andersen G, et al. Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor citalopram. Stroke 1994;25(6):1099-104.
  8. Berg A, et al. Poststroke depression in acute phase after stroke. Cerebrovasc Dis 2001;12(1):14-20.
  9. Bhogal SK, et al. Heterocyclics and selective serotonin reuptake inhibitors in the treatment and prevention of poststroke depression. J Am Geriatr Soc 2005;53:1051-57.
  10. Black KG. Diagnosing depression after stroke. South Med J 1995;88(7):699-708.
  11. Charles E. Mortality and Poststroke Depression Am J Psychiatry 2004;161:1506.
  12. Choi-Kwon S, et al. Fluoxetine treatment in poststroke depression, emotional incontinence, and anger proneness: a doubleblind, placebo-controlled study. Stroke 2006;37(1):156-61.
  13. Colonna L, et al. Escitalopram is well tolerated and more efficacious than citalopram in long-term treatment of moderately depressed patients. Poster presented at the 3rd International Forum on mood and anxiety disorders, Monte Carlo, Monaco 2002;27-30.
  14. Diequez S, et al. Is poststroke depression a vascular depression? J Neurol Sci 2004;226(1-2):53-8.
  15. Duman RS, et al. Arch Gen Psyhiatry 199;54:597.
  16. Erfurth A, et al. Depressive disorders in neurologic rehabilitation: therapy with paroxetine. Psychiatr Prax 2001;28(1):43-4.
  17. Feys HM, et al. Stroke 1998;29:785.
  18. Hackett ML, et al. Management of depression after stroke: A systematic review of pharmacological therapies. Stroke 2005;36:1098-103.
  19. Hackett ML, Anderson CS. Predictors of depression after stroke: A systematic review of observational studies. Stroke 2005;36:2296-301.
  20. Hallet M. Brain Res Rev 2001;36:169.
  21. Huff W, et al. Poststroke depression: diagnosis and therapy. Fortschr Neurol Psychiatr 2001; 69(12):581-91.
  22. Gresham GE, et al. Stroke 1997;28:1522.
  23. Gonzalez-Torrecillas JL, et al. Effects of early treatment of poststroke depression on neuropsychological rehabilitation. Int Psychogeriatr 1995;7(4):547-60.
  24. Iacoboni M, et al. Poststroke depression: relationships with morphological damage and cognitive over time. Int J Neurol Sci 1995;16:209-15.
  25. Kauhanen M, et al. Poststroke depression correlates with cognitive impairment and neurological deficits. Stroke 1999;30(9):1875-80.
  26. Kim JS, Choi-Kwon S. Poststroke depression and emotional incontinence: correlation with lesion location. Neurology 2000;54(9):1805-10.
  27. Kwakkel G, et al. Neurol Neurosurg Psyhiatr 2002;72:473.
  28. Lepola UM, et. al. Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharrnacol 2003;18:211-17.
  29. Linden T, et al. Depressive disorders after 20 months in elderly stroke patients: A case-control study. Stroke 2007;38:1860-63.
  30. Mayo NE, et al. Activity, participation, and quality of life 6 months poststroke. Arch Phys Med Rehabil 2002;83(8):1035-42.
  31. Narushima K, et al. Preventing poststroke depression: a 12-week double-blind randomized treatment trial and 21-month follow-up. J Nerv Ment Dis 2002;190(5):296-303.
  32. Paolucci S, et al. Stroke 2003;34:2861.
  33. Paolucci S, et al. Functional outcome in stroke inpatient rehabilitation: Predicting no, low and high response patients. Cerebrovasc Dis 1998;8:228-34.
  34. Paradiso S, Robinson RG. Gender differences in poststroke depression. J Neuropsychiatry Clin Neurosci 1998; 10(1):41-7.
  35. Pohjasvaara T, et al. Frequency and clinical determinants of poststroke depression. Stroke 1998; 29(11):2311-17.
  36. Ramasubbu R, et al. Functional impairment associated with acute poststroke depression: the Stroke Data Bank Study. J Neuropsychiatry Clin Neurosci 1998;10(1):26-33.
  37. Robinson RG, et al. Depression and cerebrovascular disease. J Clin Psychiatry 1990;51:26-31; discussion 32-3.
  38. Robinson RG, et al. Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial. JAMA 2008;299(20):2391-400.
  39. Sanchez C, Kreilgaard M. R-citalopram ingibits functional and 5-HTP-evoked behavioural responses to the SSRI, escitalopram. Pharmacol Biochem Behav 2004;77:391-98.
  40. Sato P, et al. Neuroanatomic and functional correlates of depressed mood: the Cardiovascular Health Study. Am J Epidemiol 1999;150:919-29.
  41. Sandor H, et al. Clinical evaluation of the efficacy and safety of paroxetin in poststroke depression: results from a phase 4, open label, multicentre clinical trial with 26 weeks of follow-up. Orv Hetil 2006;147(50):2397-404.
  42. Schwartz JA, et al. Depression in stroke rehabilitation. Biol Psychiatry 1993;33(10):694-9.
  43. Shima S, et al. Poststroke depression: Gen Hosp Psychiatry 1994;16(4): 286-9.
  44. Shimoda K, Robinson RG. The relationship between poststroke depression and lesion location in long-term follow-up. Biol Psychiatry 1999;45(2):187-92.
  45. Tange A, et al. Acta Psychiatr Scand 1997;96:134.
  46. Thomas SA, Lincoln NB. Factors relating to depression after stroke. Br J Clin Psychol 2006;45:49-61.
  47. van de Meent H, et al. Pharmacologic treatment of poststroke depression: A systematic review of the literature. Top Stroke Rehabil 2003;10:79-92.
  48. Varga D. Neuropsychiatric complications after stroke. Ideggyogy Sz 2002;55(3-4):128-36.
  49. Verdelho A, Henon H. Depressive symptoms after stroke and relationship with dementia: a three-year follow-up study. Neurology 2004;62(6):905-11.
  50. Wiart L, et al. Fluoxetine in early poststroke depression: a double-blind placebo-controlled study. Stroke 2000;31(8):1829-32.
  51. Williams LS, Ghose SS, Swinde R.W. Depression and other mental health diaognoses increase mortality riskafter ischemic stroke. Am J Psychiatry 2004;161(6):1090-5.
  52. Whyte E, Mulsant B. Poststroke depression: epidemiology, pathophysiology, and biological treatment. Biol Psychiatry 2002;52(3):253.
  53. Yamakawa Y, et al. Efficacy of milnacipran on poststroke depression on inpatient rehabilitation. Psychiatry Clin Neurosci 2005;59(6):705-10.
  54. Zigmond AS, Snaith PP. Acta Psychiatr Scand 1983;67:361.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies